with 99.9% of the lenacapavir group not acquiring HIV infection. The results will be published in The New England Journal of ...

HealthDay News — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next five years, according to research published in the ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

A UNM researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Tremendous successes have been achieved in treating and caring for people living with HIV and in developing HIV prevention technologies such as pre-exposure prophylaxis (PrEP) and post-exposure ...

The article, Safety of Kidney Transplantation from Donors with HIV, details findings supporting HIV-to-HIV kidney transplants as safe and just as effective as those using organs from donors without ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, linking these discriminatory policies to delays in effective HIV treatment ...

Patients presenting to emergency departments with opioid overdose have high rates of hepatitis C virus (HCV) infect ...

(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...